410 related articles for article (PubMed ID: 32671454)
21. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
22. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features.
Hao S; Sanger W; Onciu M; Lai R; Schlette EJ; Medeiros LJ
Mod Pathol; 2002 Dec; 15(12):1266-72. PubMed ID: 12481006
[TBL] [Abstract][Full Text] [Related]
23. [Pitfalls and update in haematopathology. Case 2. "Early phase" mantle cell lymphoma of the lymph node].
Copie-Bergman C
Ann Pathol; 2012 Oct; 32(5):336-40. PubMed ID: 23141941
[No Abstract] [Full Text] [Related]
24. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
[No Abstract] [Full Text] [Related]
25. Derivative (14)t(11;14)(q13;q32)t(11;14)(p11.2;p11.2): a novel unbalanced variant of the t(11;14)(q13;q32) translocation in mantle cell lymphoma.
Sathanoori M; Shekhter-Levin S; Marks SM; Swerdlow SH
Cancer Genet Cytogenet; 2007 Jan; 172(2):158-64. PubMed ID: 17213026
[TBL] [Abstract][Full Text] [Related]
26. Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma.
Gazzo S; Felman P; Berger F; Salles G; Magaud JP; Callet-Bauchu E
Haematologica; 2005 Dec; 90(12):1708-9. PubMed ID: 16330452
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
28. Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
Liu W; Chen X; Fan J; Zhu M; Shen H; Chen X; Chen G; Duan Y; He B; Zeng Z; Wu D; Pan J; Huang H
Br J Haematol; 2021 Nov; 195(4):634-637. PubMed ID: 34528238
[No Abstract] [Full Text] [Related]
29. Mantle Cell Lymphoma.
Cheah CY; Seymour JF; Wang ML
J Clin Oncol; 2016 Apr; 34(11):1256-69. PubMed ID: 26755518
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia with t(6;14) (p21;q32) CCND3-IGH: CCND3 rearrangement does not necessarily define a cyclin D1-negative mantle cell lymphoma.
Zhao Y; McCracken J; Rehder C; Wang E
Hematol Oncol; 2022 Feb; 40(1):111-114. PubMed ID: 34596253
[No Abstract] [Full Text] [Related]
31. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
33. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
35. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
Ettleson M; Bongers KS; Vitale K; Perissinotti AJ; Phillips T; Marini BL
J Oncol Pharm Pract; 2019 Apr; 25(3):731-734. PubMed ID: 29385883
[TBL] [Abstract][Full Text] [Related]
36. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Romaguera JE; Lee HJ; Tarapore R; Prabhu V; Allen J; Schalop L; Zloza A; Ok CY; Sadimin ET; Schenkel J; Badillo M; Wang M
Br J Haematol; 2019 Apr; 185(1):133-136. PubMed ID: 29740811
[No Abstract] [Full Text] [Related]
37. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
38. Mantle cell lymphoma: clinicopathologic features and treatments.
Kauh J; Baidas SM; Ozdemirli M; Cheson BD
Oncology (Williston Park); 2003 Jun; 17(6):879-91, 896; discussion 896-8. PubMed ID: 12846128
[TBL] [Abstract][Full Text] [Related]
39. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches.
Dreyling M;
Am Soc Clin Oncol Educ Book; 2014; ():191-8. PubMed ID: 24857076
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
